Delivering nucleic acid medicines from promise to performance

From concept to clinic, Mirai Bio helps partners design, deliver, and advance genetic medicines with greater precision, speed, and translational confidence.

Design

Co-optimize cargo and delivery strategy from the start
Delivery

Build base or targeted LNPs for specific cells and tissues
Manufacturing

Advance with development and manufacturability in view early

The industry’s first integrated end-to-end platform for genetic medicine delivery

Built for partners who require more from delivery

We’re enabling the leading innovators in genome engineering, tRNA, mRNA, DNA, and more. Whether the challenge is extrahepatic access, cell-specific targeting, formulation refinement, or development planning, Mirai is built to help partners make delivery a source of advantage.

Partner with Mirai

Better genetic medicines require delivery built for the biology

A promising cargo is only part of the answer. Delivery has to fit the target cell, tissue, route, and development path. Mirai develops LNP systems for specific biological contexts, including extrahepatic delivery, with growing proof across immune cells and other high-value targets.

Delivery innovation:

Liver

CNS

Lung

Immune Cells

Pancreas

Muscle

Fat Cell

HSCs

Kidney

Vaccines

An integrated platform to reduce fragmentation across genetic medicine development

Mirai integrates design, delivery, and development so partners can move from concept to translation-ready asset with fewer handoffs and less rework.

An end-to-end platform for targeted genetic medicine development

Mirai combines proprietary in vivo data, machine learning-guided optimization, modular LNP design, and process development capabilities to improve delivery performance while keeping translation in view from the beginning.

Nucleic acids carry the code. Delivery determines how far they go.

1

Define the delivery strategy

Align cargo, target biology, cell or tissue objective, and development goals early so delivery is built as part of the product, not added later.
2

Refine in vivo

Use high-throughput in vivo screening and ML-guided optimization to identify high-performing formulations and improve potency, selectivity, and tolerability.
3

Advance for translation

Integrate process development and manufacturability planning early to support NHP studies and GMP-aligned development.

From delivery to development, the future of genetic medicines is here

Experience across delivery, development, and translation

Mirai brings together industry leaders with expertise in lipid chemistry, in vivo biology, technical development, and nucleic acid process development to help partners build translatable medicines.

Leadership